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Introduction {#sec005}
============

Although the incidence of gastric cancer has been declining for several decades, it remains the fifth most common cancer and the third most common cause of cancer-related death worldwide \[[@pone.0144420.ref001],[@pone.0144420.ref002]\]. Gastric cancer can be classified histologically into various types \[[@pone.0144420.ref003]\]. Signet ring cell carcinoma is a distinct histological type with cells containing abundant intracytoplasmic mucin \[[@pone.0144420.ref004]\]. It has been reported that 3.4% to 29% of gastric cancers are signet ring cell carcinomas \[[@pone.0144420.ref005]--[@pone.0144420.ref009]\]. Although some studies have reported on the clinicopathological features and prognosis of signet ring cell carcinoma of the stomach, results have been inconsistent, with some studies reporting a better prognosis compared with other gastric cancers \[[@pone.0144420.ref006],[@pone.0144420.ref007],[@pone.0144420.ref010]\], and others reporting a worse prognosis \[[@pone.0144420.ref009],[@pone.0144420.ref011],[@pone.0144420.ref012]\]. Therefore, the objective of this study was to investigate differences in clinicopathologic features and survival between signet ring cell carcinoma and other histological types of gastric cancer.

Materials and Methods {#sec006}
=====================

Patients {#sec007}
--------

From 2000 to 2008, 1464 patients with histologically confirmed primary gastric adenocarcinoma underwent curative gastrectomy at the Department of Gastric Cancer and Soft Tissue Sarcoma, Fudan University Shanghai Cancer Center. Exclusion criteria for this study were as follows: (1) surgery status unknown; (2) vital status unknown; (3) incomplete pathological data. Signet ring cell carcinoma was defined as an adenocarcinoma with the presence of \>50% of tumor cells (signet ring cells) with prominent intracytoplasmic mucins \[[@pone.0144420.ref013]\]. Data were retrieved from operative and pathological reports, and follow-up data were obtained by phone, outpatient and clinical databases. Written informed consent was obtained from all patients, and the study was approved by the Ethical Committee of Fudan University Shanghai Cancer Center.

Preoperative evaluation and treatment {#sec008}
-------------------------------------

Preoperative examinations and staging was performed by endoscopic examination and computed tomography scan. Staging was carried out according to the American Joint Committee on Cancer (AJCC) TNM Staging Classification for Carcinoma of the Stomach (Seventh Edition, 2010). Gastrectomy was performed in accordance with the Japanese Classification of Gastric Carcinoma.

Immunohistochemical staining {#sec009}
----------------------------

The expression of p21, p53, c-myc and EGFR in primary lesions were detected by immunohistochemistry. All primary antibodies and mouse monoclonal antibodies were purchased from Dako (Hamburg, Germany). The detailed sources, concentrations of antibody and positive sites were as follows: anti-p21 (clone SX118), 1:50 dilution, nucleus; anti-p53 (clone DO-7), 1:100 dilution, nucleus; anti-c-myc (clone 9E10), 1:100 dilution, cytoplasm; anti-EGFR (clone E30), 1:50 dilution, cytoplasm or membrane. The staining procedures followed supplier' instructions. Negative controls were subjected to the same procedure except that the first antibody was replaced by PBS.

Immunohistochemical Staining Scores {#sec010}
-----------------------------------

All slides were evaluated by two pathologists without knowledge of patients' clinical data. The percentage of immunoreactive cells was graded on a scale of 0 to 4: no staining was scored as 0, 1--10% of cells stained scored as 1, 11--50% as 2, 51--80% as 3, and 81--100% as 4. Staining intensity was graded from 0 to 3: 0 was defined as negative, 1 as weak, 2 as moderate, and 3 as strong. The raw data were converted to an immunohistochemical score (IHS) by multiplying the quantity and intensity scores. An IHS score of 9--12 was categorized as strong immunoreactivity (+++), 5--8 as moderate (++), 1--4 as weak (+), and 0 as negative (-). On the final analysis, the cases with an HIS of less than 1 were classified as negative, and ≥ 1 as positive. These criteria were based on previously published reports \[[@pone.0144420.ref014]\].

Follow-up {#sec011}
---------

Follow-up of all patients was carried out according to our hospital's standard protocol (every three months for at least 2 years, every six months for the next 3 years, and thereafter every 12 months for life) \[[@pone.0144420.ref014]\]. The check-up items included physical examination, tumor-marker examination, ultrasound, chest radiography, computed tomographic scan, and endoscopic examination. The median follow-up time was 64 months for living patients.

Statistical analysis {#sec012}
--------------------

The patients' features and clinicopathological characteristics were analyzed using the χ^2^ test for categorical variables. Five-year survival rate was calculated by the Kaplan-Meier method, and differences between survival curves were calculated by the long-rank test. Independent prognostic factors were analyzed by multivariate survival analysis using the Cox proportional hazards model. The accepted level of significance was *P* \<0.05. Statistical analyses and graphics were performed using the SPSS 13.0 statistical package (SPSS, Inc., Chicago, IL).

Results {#sec013}
=======

Clinicopathological characteristics {#sec014}
-----------------------------------

Of 1464 patients, there were 1022 males and 442 females (2.3:1) with a mean age of 58 years. 138 patients (9.4%) had signet ring cell carcinoma and 1326 patients (90.6%) had non-signet ring cell carcinoma. By histological type, there were 35 well-differentiated tumors, 443 moderately-differentiated tumors, and 848 poorly-differentiated tumors in non-signet ring cell patients. By tumor location, 506 patients (34.6%) had tumors located in the upper third of the stomach, 248 (16.9%) had tumors in the middle third, 633 (43.2%) had tumors in the lower third, and 77 (5.3%) had tumors occupying two-thirds or more of the stomach. There were 111 (7.6%) patients with a family history of gastric cancer. The distribution of pathological stage was as follows: 346 (23.6%) stage I, 340 (23.2%) stage II, 778 (53.1%) stage III. Patients demographics were listed in [Table 1](#pone.0144420.t001){ref-type="table"}.

10.1371/journal.pone.0144420.t001

###### Patient Cohort.

![](pone.0144420.t001){#pone.0144420.t001g}

                                     n = 1464   100%
  ---------------------------------- ---------- ------
  Tumor subtype                                 
      Signet-ring cell carcinoma     138        9.4
      Other adenocarcinoma           1326       90.6
  Sex                                           
      Male                           1022       69.8
      Female                         442        30.2
  Age (yr)                                      
      \<60                           767        52.4
      ≥60                            697        47.6
  Tumor size (cm)                               
      \<5                            902        61.6
      ≥5                             562        38.4
  Tumor location                                
      Upper third                    506        34.6
      Middle third                   248        16.9
      Lower third                    633        43.2
      Two-third or more              77         5.3
  Venous tumor emboli                           
      Yes                            524        35.8
      No                             940        64.2
  Nervous invasion                              
      Yes                            564        38.5
      No                             900        61.5
  Serosa invasion                               
      Yes                            676        46.2
      No                             788        53.8
  Lymph node metastasis                         
      Yes                            501        34.2
      No                             963        65.8
  TNM stage                                     
      Stage I                        346        23.6
      Stage II                       340        23.2
      Stage III                      778        53.1
  Family history of gastric cancer              
      Yes                            111        7.6
      No                             1353       92.4
  P21 expression                                
      Positive                       949        64.8
      Negative                       515        35.2
  P53 expression                                
      Positive                       1052       71.9
      Negative                       412        28.1
  c-myc expression                              
      Positive                       929        63.5
      Negative                       535        36.5
  EGFR expression                               
      Positive                       581        39.7
      Negative                       883        60.3

Clinicopathologic characteristics were compared between signet ring cell carcinoma (SRC) and non-signet ring cell carcinoma (NSRC). Signet ring cell carcinoma presented at a younger age (*P* = 0.014); presented more frequently in females (*P* = 0.003). Patients with signet ring cell carcinoma were more likely to present with stage III disease (*P* = 0.003) ([Table 2](#pone.0144420.t002){ref-type="table"}).

10.1371/journal.pone.0144420.t002

###### Comparison of the Clinicopathological Characteristics of Patients With Signet-Ring Cell Carcinoma (SRC) and non-signet ring cell carcinoma (NSRC).

![](pone.0144420.t002){#pone.0144420.t002g}

  Variables                          SRC n = 138   NSRC n = 1326   *P*
  ---------------------------------- ------------- --------------- ---------
  Gender                                                           0.003
      Male                           81            941             
      Female                         57            385             
  Age (yr)                                                         0.014
      \<60                           86            681             
      ≥60                            52            645             
  Tumor size (cm)                                                  0.851
      \<5                            84            818             
      ≥5                             54            508             
  Tumor location                                                   \<0.001
      Upper third                    22            484             
      Middle third                   34            214             
      Lower third                    68            565             
      Two-third or more              14            63              
  Venous tumor emboli                                              0.501
      Yes                            53            471             
      No                             85            855             
  Nervous invasion                                                 0.602
      Yes                            56            508             
      No                             82            818             
  Serosa invasion                                                  0.344
      Yes                            69            607             
      No                             69            719             
  Lymph node metastasis                                            0.325
      Yes                            96            867             
      No                             42            459             
  TNM stage                                                        \<0.001
      Stage I                        35            311             
      Stage II                       13            327             
      Stage III                      90            688             
  Family history of gastric cancer                                 0.876
      Yes                            10            101             
      No                             128           1225            
  P21 expression                                                   \<0.001
      Positive                       66            883             
      Negative                       72            443             
  P53 expression                                                   0.009
      Positive                       86            966             
      Negative                       52            360             
  c-myc expression                                                 0.111
      Positive                       79            850             
      Negative                       59            476             
  EGFR expression                                                  0.292
      Positive                       49            532             
      Negative                       89            794             

The expression of p21, p53, c-myc, and EGFR {#sec015}
-------------------------------------------

The expression of p21, p53, c-myc, and EGFR were analyzed by immunohistochemical staining. Staining location was predominantly cell cytoplasm for c-myc, cell cytoplasm or membrane for EGFR, and nucleus for p21 and p53 ([Fig 1](#pone.0144420.g001){ref-type="fig"}). The positive expression rates of p21, p53, c-myc, and EGFR were 64.8%, 71.9%, 63.5%, and 39.7%, respectively. Relative expression of p21 and p53 was less in SRC than in NSRC, and the difference was significant.

![Positive expression of biological markers by immunohistochemistry in gastric cancer tissue.\
A) Positive expression of p21. B) Positive expression of p53. C) Positive expression of c-myc. D) Positive expression of EGFR.](pone.0144420.g001){#pone.0144420.g001}

Univariate Analysis {#sec016}
-------------------

The overall 5-year survival rate was 49% for all patients. The 5-year survival rates of SRC and NSRC were 36.2% and 49.5%, and the differences were statistically significant ([Fig 2](#pone.0144420.g002){ref-type="fig"}). In addition to tumor subtype, the significant prognostic factors were age, tumor size, tumor location, venous tumor emboli, nervous invasion, serosa invasion, lymph node metastasis, TNM stage, and EGFR expression ([Table 3](#pone.0144420.t003){ref-type="table"}). In SRC, univariate analysis showed that age, tumor size, tumor location, venous tumor emboli, nervous invasion, serosa invasion, lymph node metastasis, TNM stage, and EGFR expression were significant prognostic factors ([Table 4](#pone.0144420.t004){ref-type="table"}). In NSRC, univariate analysis showed that age, tumor size, tumor location, venous tumor emboli, nervous invasion, serosa invasion, lymph node metastasis, TNM stage, and EGFR expression significantly affected prognosis ([Table 5](#pone.0144420.t005){ref-type="table"}).

![Kaplan-Meier survival curves by histological type.\
There were significant differences between SRC and NSRC (*P* \<0.001).](pone.0144420.g002){#pone.0144420.g002}

10.1371/journal.pone.0144420.t003

###### Univariate analysis of all patients by Kaplan-Meier method.

![](pone.0144420.t003){#pone.0144420.t003g}

  Variable                             n      5-Year survival rate (%)   *P* value
  ------------------------------------ ------ -------------------------- -----------
  Sex                                                                    0.989
      Male                             1022   48.0                       
      Female                           442    48.6                       
  Age (yr)                                                               \<0.001
      \<60                             767    53.5                       
      ≥60                              697    42.5                       
  Tumor subtype                                                          \<0.001
      Signet ring cell carcinoma       138    36.2                       
      Non-signet ring cell carcinoma   1326   49.5                       
  Tumor size (cm)                                                        \<0.001
      \<5                              902    57.5                       
      ≥5                               562    33.3                       
  Tumor location                                                         \<0.001
      Upper third                      506    38.1                       
      Middle third                     248    44.4                       
      Lower third                      633    61.3                       
      Two-third or more                77     19.5                       
  Venous tumor emboli                                                    \<0.001
      Yes                              524    26.7                       
      No                               940    60.2                       
  Nervous invasion                                                       \<0.001
      Yes                              564    28.9                       
      No                               900    60.3                       
  Serosa invasion                                                        \<0.001
      Yes                              676    28.4                       
      No                               788    65.2                       
  Lymph node metastasis                                                  
      Yes                              963    30.8                       \<0.001
      No                               501    81.6                       
  TNM stage                                                              \<0.001
      Stage I                          346    93.1                       
      Stage II                         340    58.5                       
      Stage III                        778    23.8                       
  P21 expression                                                         0.497
      Positive                         949    47.1                       
      Negative                         515    50.3                       
  P53 expression                                                         0.901
      Positive                         1052   48.4                       
      Negative                         412    47.8                       
  c-myc expression                                                       0.391
      Positive                         929    47.6                       
      Negative                         535    49.3                       
  EGFR expression                                                        0.012
      Positive                         581    43.7                       
      Negative                         883    51.2                       

10.1371/journal.pone.0144420.t004

###### Kaplan-Meier univariate analysis of patients with SRC.
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  Variable                n    5-Year survival rate (%)   *P* value
  ----------------------- ---- -------------------------- -----------
  Sex                                                     0.319
      Male                81   34.6                       
      Female              57   38.6                       
  Age (yr)                                                0.012
      \<60                86   43.0                       
      ≥60                 52   25.0                       
  Tumor size (cm)                                         \<0.001
      \<5                 84   48.8                       
      ≥5                  54   16.7                       
  Tumor location                                          \<0.001
      Upper third         22   18.2                       
      Middle third        34   29.4                       
      Lower third         68   51.5                       
      Two-third or more   14   7.1                        
  Venous tumor emboli                                     \<0.001
      Yes                 53   15.1                       
      No                  85   49.4                       
  Nervous invasion                                        \<0.001
      Yes                 56   21.4                       
      No                  82   46.3                       
  Serosa invasion                                         \<0.001
      Yes                 69   17.4                       
      No                  69   55.1                       
  Lymph node metastasis                                   \<0.001
      Yes                 96   16.7                       
      No                  42   81.0                       
  TNM stage                                               \<0.001
      Stage I             35   91.4                       
      Stage II            13   53.8                       
      Stage III           90   12.2                       
  P21 expression                                          0.490
      Positive            66   36.4                       
      Negative            72   36.1                       
  P53 expression                                          0.423
      Positive            86   34.9                       
      Negative            52   38.5                       
  c-myc expression                                        0.202
      Positive            79   31.6                       
      Negative            59   42.4                       
  EGFR expression                                         0.012
      Positive            49   26.5                       
      Negative            89   41.6                       

10.1371/journal.pone.0144420.t005

###### Kaplan-Meier univariate analysis of patients with NSRC.

![](pone.0144420.t005){#pone.0144420.t005g}

  Variable                n     5-Year survival rate (%)   *P* value
  ----------------------- ----- -------------------------- -----------
  Sex                                                      0.960
      Male                941   49.2                       
      Female              385   50.1                       
  Age (yr)                                                 \<0.001
      \<60                681   54.8                       
      ≥60                 645   43.9                       
  Tumor size (cm)                                          \<0.001
      \<5                 818   58.4                       
      ≥5                  508   35.0                       
  Tumor location                                           \<0.001
      Upper third         484   39                         
      Middle third        214   46.7                       
      Lower third         565   62.5                       
      Two-third or more   63    22.2                       
  Venous tumor emboli                                      \<0.001
      Yes                 471   28.0                       
      No                  855   61.3                       
  Nervous invasion                                         \<0.001
      Yes                 508   29.7                       
      No                  818   61.7                       
  Serosa invasion                                          \<0.001
      Yes                 893   33.4                       
      No                  433   82.7                       
  Lymph node metastasis                                    \<0.001
      Yes                 867   32.4                       
      No                  459   81.7                       
  TNM stage                                                \<0.001
      Stage I             311   93.2                       
      Stage II            327   58.7                       
      Stage III           688   25.3                       
  P21 expression                                           0.173
      Positive            883   47.9                       
      Negative            443   52.6                       
  P53 expression                                           0.924
      Positive            966   49.6                       
      Negative            360   49.2                       
  c-myc expression                                         0.510
      Positive            850   49.1                       
      Negative            476   50.2                       
  EGFR expression                                          0.037
      Positive            532   45.3                       
      Negative            794   52.3                       

Multivariate Analysis {#sec017}
---------------------

Multivariate analysis was used to determine the independent prognostic factors for gastric cancer patients. Multivariate analysis by the Cox proportional hazard model found that tumor subtype, age, tumor size, venous tumor emboli, nervous invasion, TNM stage, and EGFR expression were independent prognostic factors for all the patients ([Table 6](#pone.0144420.t006){ref-type="table"}). In SRC, multivariate analysis showed that age, TNM stage, and EGFR expression were independent prognostic factors. In NSRC, multivariate analysis showed that age, tumor size, venous tumor emboli, and TNM stage were independent prognostic factors for prognosis.

10.1371/journal.pone.0144420.t006

###### Multivariate analysis of patients by Cox model.

![](pone.0144420.t006){#pone.0144420.t006g}

  Variable                     *P* value   RR      95% CI
  ---------------------------- ----------- ------- --------------
  Age                          0.000       1.310   1.132--1.516
  Signet ring cell carcinoma   0.000       1.798   1.432--2.257
  Tumor size                   0.003       1.249   1.079--1.445
  Tumor location               0.281       0.960   0.892--1.034
  Venous tumor emboli          0.000       1.460   1.248--1.707
  Nervous invasion             0.013       1.227   1.045--1.442
  Serosa invasion              0.983       1.002   0.840--1.195
  Lymph node metastasis        0.398       1.169   0.814--1.679
  TNM stage                    0.000       2.918   2.284--3.727
  EGFR                         0.038       1.168   1.009--1.352

Comparison of Survival According to Stage Between SRC and NSRC Groups {#sec018}
---------------------------------------------------------------------

According to the AJCC/TNM staging, gastric cancer patients are classified into stage I, II, or III. Histopathologically, tumors in each stage are classified as SRC or NSRC. There were significant differences of overall survival rates between SRC and NSRC in stage III (*P* \<0.001, [Fig 3](#pone.0144420.g003){ref-type="fig"}).

![Comparison of survival according to tumor stage.\
There were significant differences between SRC and NSRC according to stage III (*P* \<0.001).](pone.0144420.g003){#pone.0144420.g003}

Discussion {#sec019}
==========

The main findings of this study were as follows: (1) Signet ring cell carcinoma was an independent prognostic factor for five year gastric cancer. In particular, there was a significant difference in the survival of patients with stage III between SRC and NSRC. (2) There were differences in prognostic factors between SRC and NSRC, and EGFR expression was an independent predictor of poor prognosis for patients with SRC, but not for those with NSRC.

According to the Japanese gastric cancer classification system, tumors are classified by histological subtype as classical adenocarcinomas, signet ring cell carcinoma, mucinous adenocarcinoma, or other rare types \[[@pone.0144420.ref015]\]. Although some studies have shown that histological subtype is a key factor for tumor biology and prognosis, published results have been inconsistent \[[@pone.0144420.ref006], [@pone.0144420.ref007], [@pone.0144420.ref009]--[@pone.0144420.ref012]\]. In contrast to TNM staging, histological subtype is not incorporated in clinical classification systems.

In view of the inconsistent literature, we decided to evaluate the clinicopathological features and prognostic significance of SRC in our large single-center sample. In the current study, the incidence of SRC was 9.4% of gastric cancers, which was similar to incidence in previous reports \[[@pone.0144420.ref005]--[@pone.0144420.ref009]\]. We found that signet ring cell carcinoma had different clinicopathological features compared to other types of gastric carcinoma. SRC occurred more frequently in female and in younger patients than NSRC. This was also similar to the demographics reported in the previous studies \[[@pone.0144420.ref006], [@pone.0144420.ref008]\], though the exact reason remains unclear. It has been reported that histology may be influenced by sex hormones \[[@pone.0144420.ref016]\], but more research is needed to investigate the association between age, sex and gastric cancer histopathological type. Our sample also showed that SRC and NSRC tended to present at different anatomic locations, with SRC occurring more frequently in the middle third of the stomach. This was consistent with the findings of Ostuji et al. \[[@pone.0144420.ref007]\] and Zhang et al. \[[@pone.0144420.ref012]\]. Some previous studies have shown that SRC develops from the fundic glands, which are predominantly located in the fundus and body of the stomach \[[@pone.0144420.ref007], [@pone.0144420.ref017]\]. In contrast, Kim et al. \[[@pone.0144420.ref018]\] did not find differences in tumor location between SRC and NSRC. We also found that patients with signet ring cell carcinoma were more likely to present at more advanced stages, including a greater proportion of patients with stage III. Finally, on IHC biomarker analysis we found that the expression of p21 and p53 were significantly different between SRC and NSRC. In aggregate, the differences we identified between SRC and NSRC indicate that SRC may present a distinct and more aggressive disease.

In the current study, the 5-yr survival rate of patients with SRC was 36.2%, significantly shorter than patients with NSRC. Multivariate analysis showed that signet ring cell was an independent prognostic factors. However, this result could be related to the higher proportion of advanced stage tumors among SRC patients. In order to exclude the influence of disease stage at the time of presentation, we performed a subgroup analysis by tumor stage, which showed no significant differences in overall survival rates between SRC and NSRC in stage I and II. However, in stage III tumors, the prognosis was poorer in SRC than NSRC. These results were similar to previous studies \[[@pone.0144420.ref017], [@pone.0144420.ref019], [@pone.0144420.ref020]\]. Kim et al. \[[@pone.0144420.ref017]\] reported that the prognosis of early gastric carcinoma with SRC was similar to other types of gastric carcinoma. Li et al. \[[@pone.0144420.ref019]\] and Piessen et al. \[[@pone.0144420.ref020]\] found that the 5-yr survival rate of SRC was significantly poorer than that of NSRC in advanced gastric carcinoma.

In addition, we found that EGFR expression was an independent prognostic factor for patients with SRC by multivariate analysis, while it was not for those with NSRC. Given that SRC was not sensitive to common chemotherapeutic agents, the results of this study, indicating the association of EGFR expression and poor prognosis in SRC, may facilitate further development of agents targeting EGFR expression and clinical trials evaluating the role of those agents in SRC.

Conclusion {#sec020}
==========

SRC is a distinct type of gastric carcinoma in terms of clinicopathological features and prognosis. SRC presents with more advanced stage than NSRC, and carries a worse prognosis.
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